AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17805061 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction carboplatin (AUC = 5.5) on days 1 and 22, vinorelbine (25 mg/m2) on days 1, 8, 22, and 29, followed by intravenous topotecan (0.5 mg/m2) on days 43 to 47, days 57 to 61, and days 71 to 75 with accelerated radiotherapy (RT) at 2 Gy per fraction, twice daily for five consecutive days, every other week, to a cumulative dose of 60 Gy during a 5-week period.
Number of subjects: 35
Study 15087615 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS guided
Number of subjects: 60
Study 15087615 — intervention group
Group type: EXPERIMENTAL
Intervention: AAI guided
Number of subjects: 60
Study 15087615 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 11310690 — intervention group
Group type: EXPERIMENTAL
Intervention: IV tubing replaced within 3 days
Number of subjects: 512
Study 11310690 — intervention group
Group type: COMPARATOR
Intervention: IV tubing replaced within 4 to 7 days
Number of subjects: 512
Study 9065294 — intervention group
Group type: EXPERIMENTAL
Intervention: Decontamination with polymyxin B (100 mg), tobramycin (80 mg), vancomycin (125 mg), and amphotericin B (500 mg) four times per day orally from the day before the operation until the seventh postoperative day
Number of subjects: 205
Study 9065294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study 9065294 — intervention group
Group type: EXPERIMENTAL
Intervention: Decontamination
Number of subjects: 205
Study 7930223 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactor risk reduction program
Number of subjects: 300
Study 7930223 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 300
Study 2906153 — intervention group
Group type: EXPERIMENTAL
Intervention: m-chlorophenyl-piperazine (MCPP) (0.25 mg/kg)
Number of subjects: 45
Study 2906153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 31206225 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin supplementation (500 mg per day)
Number of subjects: 60
Study 31206225 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 28937706 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole lauroxil 441 mg
Number of subjects: 181
Study 28937706 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole lauroxil 882 mg
Number of subjects: 181
Study 26558530 — intervention group
Group type: EXPERIMENTAL
Intervention: Care management
Number of subjects: 1018
Study 26558530 — intervention group
Group type: COMPARATOR
Intervention: Monitoring alone
Number of subjects: 1018
Study 23791894 — intervention group
Group type: EXPERIMENTAL
Intervention: Eugenol
Number of subjects: 0
Study 23791894 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvacrol
Number of subjects: 0
Study 23791894 — intervention group
Group type: EXPERIMENTAL
Intervention: Eugenol and Carvacrol
Number of subjects: 0
Study 21377140 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Laparoscopic Hysterectomy (TLH)
Number of subjects: 0
Study 21377140 — intervention group
Group type: COMPARATOR
Intervention: Vaginal Hysterectomy (VH)
Number of subjects: 0
Study 17713847 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based training
Number of subjects: 50
Study 17713847 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person training
Number of subjects: 50
Study 16735583 — intervention group
Group type: EXPERIMENTAL
Intervention: Helmet and shoulder pads
Number of subjects: 16
Study 16735583 — intervention group
Group type: EXPERIMENTAL
Intervention: Helmet removal
Number of subjects: 16
Study 16735583 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder pads
Number of subjects: 16
Study 14528504 — intervention group
Group type: EXPERIMENTAL
Intervention: lenercept 0.01 mg/kg (maximum 1 mg)
Number of subjects: 0
Study 14528504 — intervention group
Group type: EXPERIMENTAL
Intervention: lenercept 0.05 mg/kg (maximum 5 mg)
Number of subjects: 0
Study 14528504 — intervention group
Group type: EXPERIMENTAL
Intervention: lenercept 0.2 mg/kg (maximum 20 mg)
Number of subjects: 0
Study 14528504 — intervention group
Group type: EXPERIMENTAL
Intervention: lenercept 0.5 mg/kg (maximum 50 mg)
Number of subjects: 0
Study 14528504 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 11106679 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-H. pylori treatment
Number of subjects: 0
Study 11106679 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene treatment
Number of subjects: 0
Study 11106679 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid treatment
Number of subjects: 0
Study 11106679 — intervention group
Group type: EXPERIMENTAL
Intervention: Curing H. pylori infection
Number of subjects: 0
Study 9358690 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol ascending limb (AAL)
Number of subjects: 60
Study 9358690 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol descending limb (ADL)
Number of subjects: 60
Study 9358690 — intervention group
Group type: COMPARATOR
Intervention: Sober control groups
Number of subjects: 60
Study 1525531 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice from general practitioners
Number of subjects: 154
Study 1525531 — intervention group
Group type: COMPARATOR
Intervention: Control group (no advice)
Number of subjects: 154
Study 4070320 — intervention group
Group type: EXPERIMENTAL
Intervention: bezafibrate (200 mg 3-times daily)
Number of subjects: 28
Study 4070320 — intervention group
Group type: EXPERIMENTAL
Intervention: clofibrate (500 mg 3-times daily)
Number of subjects: 28
Study 4070320 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 28
Study 30003477 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-based online intervention with autonomy support and implementation intention components
Number of subjects: 202
Study 30003477 — intervention group
Group type: COMPARATOR
Intervention: Control group (received national guidelines, e-mail summary, and SMS messages)
Number of subjects: 202
Study 28077825 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of essential oil for 3 minutes at a distance of approximately 10 cm from the nose, with aroma stone beside head (within 30 cm)
Number of subjects: 60
Study 28077825 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of essential oil
Number of subjects: 60
Study 24439348 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza (TIV)
Number of subjects: 669695
Study 24439348 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetanus-diphtheria
Number of subjects: 669695
Study 24439348 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B
Number of subjects: 669695
Study 24439348 — intervention group
Group type: EXPERIMENTAL
Intervention: Measles-mumps-rubella (MMR)
Number of subjects: 669695
Study 24439348 — intervention group
Group type: EXPERIMENTAL
Intervention: Varicella
Number of subjects: 669695
Study 24439348 — intervention group
Group type: EXPERIMENTAL
Intervention: Live-attenuated influenza vaccine (LAIV)
Number of subjects: 669695
Study 22859346 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 22
Study 22859346 — intervention group
Group type: COMPARATOR
Intervention: DMARD
Number of subjects: 22
Study 20398112 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-low beds introduced in intervention wards (1 low-low bed for every 12 beds)
Number of subjects: 10937
Study 20398112 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-low beds introduced in intervention wards
Number of subjects: 10937
Study 18474113 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling treatment (hand inserted into a rigid chamber with subatmospheric pressure and cooled metal surface at 18-22 degrees C)
Number of subjects: 10
Study 15841739 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose (400/1000)
Number of subjects: 126
Study 15841739 — intervention group
Group type: COMPARATOR
Intervention: Lower dose (200/500)
Number of subjects: 126
Study 12683265 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation antipsychotic medications
Number of subjects: 0
Study 12683265 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive monitoring and warning about side effects
Number of subjects: 0
Study 10921468 — intervention group
Group type: COMPARATOR
Intervention: Loratadine (0.3 mg/kg)
Number of subjects: 28
Study 8885114 — intervention group
Group type: EXPERIMENTAL
Intervention: LTG + PHT
Number of subjects: 302
Study 8885114 — intervention group
Group type: EXPERIMENTAL
Intervention: LTG + PB
Number of subjects: 302
Study 8885114 — intervention group
Group type: EXPERIMENTAL
Intervention: LTG + CBZ
Number of subjects: 302
Study 8885114 — intervention group
Group type: EXPERIMENTAL
Intervention: LTG mono
Number of subjects: 302
Study 8885114 — intervention group
Group type: EXPERIMENTAL
Intervention: LTG + VPA + PHT
Number of subjects: 302
Study 8885114 — intervention group
Group type: EXPERIMENTAL
Intervention: LTG + VPA + CBZ
Number of subjects: 302
Study 8885114 — intervention group
Group type: EXPERIMENTAL
Intervention: LTG + VPA + PB
Number of subjects: 302
Study 8885114 — intervention group
Group type: EXPERIMENTAL
Intervention: LTG + VPA
Number of subjects: 302
Study 8885114 — intervention group
Group type: COMPARATOR
Intervention: LTG monotherapy
Number of subjects: 302
Study 8885114 — intervention group
Group type: EXPERIMENTAL
Intervention: LTG with VPA
Number of subjects: 302
Study 1577042 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 1577042 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole
Number of subjects: 0
Study 1577042 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavinton
Number of subjects: 0
Study 1577042 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 0
Study 1577042 — intervention group
Group type: COMPARATOR
Intervention: Combination of ADP with either adrenaline or PAF, adrenaline with PAF, and collagen with ADP
Number of subjects: 0
Study 6714601 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-cm flexible sigmoidoscope
Number of subjects: 96
Study 6714601 — intervention group
Group type: COMPARATOR
Intervention: 60-cm flexible sigmoidoscope
Number of subjects: 96
Study 31205211 — intervention group
Group type: EXPERIMENTAL
Intervention: Thawed plasma (5‐day shelf life)
Number of subjects: 7275
Study 31205211 — intervention group
Group type: EXPERIMENTAL
Intervention: Thawed plasma
Number of subjects: 7275
Study 31205211 — intervention group
Group type: EXPERIMENTAL
Intervention: Thawed plasma program implementation
Number of subjects: 7275
Study 29224648 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oral multivitamins and multiminerals (6 tablets daily)
Number of subjects: 460
Study 29224648 — intervention group
Group type: COMPARATOR
Intervention: Placebo (6 tablets daily)
Number of subjects: 460
Study 27056776 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual SYNTAX score (RSS) of 0
Number of subjects: 427
Study 27056776 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual SYNTAX score (RSS) >0 to 4
Number of subjects: 427
Study 27056776 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual SYNTAX score (RSS) >4 to 8
Number of subjects: 427
Study 27056776 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual SYNTAX score (RSS) >8
Number of subjects: 427
Study 27056776 — intervention group
Group type: EXPERIMENTAL
Intervention: SYNTAX revascularization index (SRI) 100%
Number of subjects: 427
Study 27056776 — intervention group
Group type: EXPERIMENTAL
Intervention: SYNTAX revascularization index (SRI) 50% to <100%
Number of subjects: 427
Study 27056776 — intervention group
Group type: EXPERIMENTAL
Intervention: SYNTAX revascularization index (SRI) 0 to <50%
Number of subjects: 427
Study 25440203 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard physiotherapy treatment accompanied by 20min knee joint distraction
Number of subjects: 40
Study 25440203 — intervention group
Group type: COMPARATOR
Intervention: Standard physiotherapy treatment alone
Number of subjects: 40
Study 22508468 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX plus etanercept
Number of subjects: 0
Study 22508468 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral triple therapy (MTX plus sulfasalazine plus hydroxychloroquine)
Number of subjects: 0
Study 22508468 — intervention group
Group type: COMPARATOR
Intervention: Step-up from MTX monotherapy to combination therapy
Number of subjects: 0
Study 20729667 — intervention group
Group type: EXPERIMENTAL
Intervention: Onyx HD‐500
Number of subjects: 13
Study 17908710 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung elastic recoil measured at total lung capacity (CR)
Number of subjects: 67
Study 17908710 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung elastic recoil measured at functional residual capacity (CRfrc)
Number of subjects: 67
Study 11340222 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional MRI in patients after stroke
Number of subjects: 28
Study 11340222 — intervention group
Group type: COMPARATOR
Intervention: Functional MRI in healthy control subjects
Number of subjects: 28
Study 11340222 — intervention group
Group type: EXPERIMENTAL
Intervention: Geometric center of activation of the primary sensorimotor cortex in patients
Number of subjects: 28
Study 11340222 — intervention group
Group type: EXPERIMENTAL
Intervention: Geometric center of activation of the primary sensorimotor cortex in patients with hand-tapping task
Number of subjects: 28
Study 9116988 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum β-carotene concentration
Number of subjects: 816
Study 9116988 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum retinol concentration
Number of subjects: 816
Study 8317392 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (64 mg n‐3 fatty acids/kg body wt)
Number of subjects: 8
Study 8317392 — intervention group
Group type: COMPARATOR
Intervention: Olive oil placebo
Number of subjects: 8
Study 3107027 — intervention group
Group type: EXPERIMENTAL
Intervention: Active diazepam (Group D)
Number of subjects: 42
Study 3107027 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group P)
Number of subjects: 42
Study 29697587 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-streamed group
Number of subjects: 67
Study 29697587 — intervention group
Group type: COMPARATOR
Intervention: Light microscopy group
Number of subjects: 67
Study 29697587 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual microscopy group
Number of subjects: 67
Study 29697587 — intervention group
Group type: EXPERIMENTAL
Intervention: Study group
Number of subjects: 67
Study 27242368 — intervention group
Group type: COMPARATOR
Intervention: Standard azathioprine maintenance therapy (1.5-2.0 mg/kg until 1 year after diagnosis, then tapering to 25 mg every 3 months)
Number of subjects: 131
Study 27242368 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended azathioprine maintenance therapy (1.5-2.0 mg/kg continued until 4 years after diagnosis, then tapered)
Number of subjects: 131
Study 27242368 — intervention group
Group type: COMPARATOR
Intervention: Standard azathioprine maintenance therapy
Number of subjects: 131
Study 27242368 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended azathioprine maintenance therapy
Number of subjects: 131
Study 27242368 — intervention group
Group type: EXPERIMENTAL
Intervention: C-ANCA positive patients at remission
Number of subjects: 131
Study 23604701 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexitol-sweetened gum containing casein phosphopeptide-amorphous calcium phosphate (CPP-ACP)
Number of subjects: 130
Study 23604701 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentitol-sweetened gum containing no CPP-ACP
Number of subjects: 130
Study 23604701 — intervention group
Group type: COMPARATOR
Intervention: Control group with no gum
Number of subjects: 130
Study 23564917 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (40% of total diet energy content as carbohydrates)
Number of subjects: 152
Study 23564917 — intervention group
Group type: COMPARATOR
Intervention: Control diet (55% of total diet energy content as carbohydrates)
Number of subjects: 152
Study 23564917 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 152
Study 23564917 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 152
Study 20511044 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous Chondrocyte Implantation (ACI)
Number of subjects: 658
Study 20511044 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoarticular Transplantation (OATS)
Number of subjects: 658
Study 20511044 — intervention group
Group type: COMPARATOR
Intervention: Microfracture
Number of subjects: 658
Study 20511044 — intervention group
Group type: EXPERIMENTAL
Intervention: Return to preinjury level of sports
Number of subjects: 658
Study 20511044 — intervention group
Group type: EXPERIMENTAL
Intervention: Defect size < 2 cm², preoperative symptoms < 18 months, no prior surgery, younger age, higher sports level
Number of subjects: 658
Study 20511044 — intervention group
Group type: COMPARATOR
Intervention: Return to sports performance
Number of subjects: 658
Study 18420532 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (8 mg) after 28 days of GBE administration
Number of subjects: 0
Study 18420532 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (8 mg) before GBE administration
Number of subjects: 0
Study 18420532 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (8 mg) after GBE administration
Number of subjects: 0
Study 15885510 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrective Feedback (CF)
Number of subjects: 0
Study 15885510 — intervention group
Group type: EXPERIMENTAL
Intervention: Errorless Learning (EL)
Number of subjects: 0
Study 15885510 — intervention group
Group type: COMPARATOR
Intervention: Standard Administration (SA)
Number of subjects: 0
Study 12651681 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic puncture assist device
Number of subjects: 60
Study 11198369 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide (NTZ)
Number of subjects: 1087
Study 11198369 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole
Number of subjects: 1087
Study 11198369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1087
Study 8636834 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Number of subjects: 112
Study 8636834 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher cognitive complexity
Number of subjects: 112
Study 8636834 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 112
Study 1735149 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive strategy (INV)
Number of subjects: 3339
Study 1735149 — intervention group
Group type: COMPARATOR
Intervention: Conservative strategy (CON)
Number of subjects: 3339
Study 31356705 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic apex locators
Number of subjects: 64
Study 31356705 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiography
Number of subjects: 64
Study 28844986 — intervention group
Group type: EXPERIMENTAL
Intervention: Service dogs
Number of subjects: 0
Study 28844986 — intervention group
Group type: COMPARATOR
Intervention: Emotional support dogs
Number of subjects: 0
Study 25962611 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia (SA) using hyperbaric bupivacaine 9 mg with fentanyl 15 µg
Number of subjects: 189
Study 25962611 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous analgesia (IVA) using remifentanil infusion 0.1 µg kg min(‐1)
Number of subjects: 189
Study 25962611 — intervention group
Group type: COMPARATOR
Intervention: Control (no anaesthetic intervention)
Number of subjects: 189
Study 25962611 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia (SA) for re-attempts
Number of subjects: 189
Study 25962611 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous analgesia (IVA) for re-attempts
Number of subjects: 189
Study 25962611 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia (SA)
Number of subjects: 189
Study 25962611 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous analgesia (IVA)
Number of subjects: 189
Study 25962611 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia (SA) and IVA
Number of subjects: 189
Study 23820501 — intervention group
Group type: EXPERIMENTAL
Intervention: OCA regimen (omeprazole 20mg, clarithromycin 500mg, amoxicillin 1g)
Number of subjects: 93
Study 23820501 — intervention group
Group type: EXPERIMENTAL
Intervention: OMAB regimen (omeprazole 20mg, metronidazole 500mg, amoxicillin 1g, bismuth subcitrate 240mg)
Number of subjects: 93
Study 23820501 — intervention group
Group type: EXPERIMENTAL
Intervention: Both OCA and OMAB regimens
Number of subjects: 93
Study 23090161 — intervention group
Group type: EXPERIMENTAL
Intervention: Postfire forearm immersion in 10 °C water
Number of subjects: 94
Study 23090161 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation
Number of subjects: 94
Study 23090161 — intervention group
Group type: EXPERIMENTAL
Intervention: Live-fire exposure
Number of subjects: 94
Study 19232611 — intervention group
Group type: EXPERIMENTAL
Intervention: dydrogesterone
Number of subjects: 180
Study 19232611 — intervention group
Group type: EXPERIMENTAL
Intervention: calcium plus vitamin D
Number of subjects: 180
Study 19232611 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 180
Study 18381950 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 100 mg twice daily
Number of subjects: 49
Study 18381950 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg twice daily
Number of subjects: 49
Study 18381950 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg twice daily (unblinded extension)
Number of subjects: 49
Study 18381950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 15765179 — intervention group
Group type: EXPERIMENTAL
Intervention: Kyphoplasty
Number of subjects: 60
Study 15765179 — intervention group
Group type: COMPARATOR
Intervention: Control (Conventional medical management)
Number of subjects: 60
Study 12200985 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose EPO (250 IU/kg)
Number of subjects: 93
Study 12200985 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose EPO (400 IU/kg)
Number of subjects: 93
Study 12200985 — intervention group
Group type: COMPARATOR
Intervention: Control group (PRBC transfusions)
Number of subjects: 93
Study 12200985 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined low and high dose EPO
Number of subjects: 93